UI Hospitals and Clinics
Participants in this study have HER2-positive primary non-metastatic breast cancer and had evidence of cancer in breast and lymph nodes after chemotherapy. Participants will receive either trastuzumab emtansine, (previously known as T-DM1) or Trastuzumab alone. Trastuzumab emtansine is an investigational drug, which means that health authorities have not approved trastuzumab emtansine for the treatment of HER2-positive primary non-metastatic breast cancer. The purpose of this research study is to find out the effects of trastuzumab emtansine versus trastuzumab and which is more effective in treating breast cancer.
Michelle Arnold 319-356-2778
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.